Changes that were made to the Clinical Decision-Making Tool on Oct. 26:
Significant changes:
- The recommendation to test a patient when antivirals are prescribed was removed. In the same bullet, an example (outbreaks in closed settings) was added.
- Treatment of children less than 2 years of age is the most current recommendation (changed from less than 5 years of age).
- AHW added two notes to remind prescribers of contra-indications and precautions related to use of antivirals (one in the algorithm, one in the table).
Minor changes to algorith:
- Signs and Symptoms of Acute ILI, under common: malaise and arthralgias were added, to be more consistent with national guidelines.
- Bloody sputum was added to the list of Indicators of Severe Illness.
- Under Risk Factors, a few wording changes were made and a few examples were added.
H1N1 Documents for Pharmacists
All documents concerning pharmacist involvement in the provincial H1N1 pandemic plan can be found on the ACP website under H1N1 – pharmacist information in the Bulletin Board section.
FAQs
- AHW answers to questions about Tamiflu dispensing program
- ACP answers to questions about H1N1 and pharmacist prescribing
Documents
- Letter from Chief Medical Officer of Health asking for pharmacist participation
- Antiviral Dispensing Policy for Pharmacists/Community Pharmacies During the Pandemic (H1N1) 2009 Response
- Clinical Decision-Making Algorithm – updated Oct. 26, 2009
- Benefact – Oct. 14, 2009
- Letter accompanying first shipment of Tamiflu to pharmacies
- Patient education sheet on Tamiflu
- Reporting adverse events – AHW letter and instructions
Originally published in the October 27, 2009, issue of The Link
